Press release
Global RNAi Therapeutics Market is Forecast to Reach a Value of USD 20.23 Billion By 2030 with a Growing CAGR of 7.69% | Infinium Global Research
To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/reports/sample-request/1610
Key Market Insights:
The global RNAi therapeutics market, valued at USD 11.20 billion in 2022, is projected to soar to USD 20.23 billion by 2030, boasting a robust CAGR of 7.69% during the forecast period 2023-2030.
Market Overview:
RNA interference (RNAi) is a biological response to double-stranded RNA, regulating gene expression and resisting both endogenous and exogenous nucleic acids. RNAi therapeutics represent an expanding class of drugs with potential applications across various diseases like oncology, cardiovascular issues, neurodegenerative disorders, and infectious diseases. These therapies target disease-causing genes, once considered undruggable, positioning them as a vital component in the pharmaceutical sector.
Market Drivers:
The burgeoning research and development efforts to address chronic diseases are propelling the RNAi therapeutics market. Rising instances of chronic conditions worldwide, coupled with technological breakthroughs, are driving market expansion. Collaborations between drug distribution companies and Contract Research Organizations (CROs) further contribute to market growth. Despite the complex delivery mechanisms hindering widespread use, advancements in delivery technology are widening clinical applications, especially in oncology and other high-demand areas.
Regional Dynamics:
North America is poised to dominate the RNAi therapeutics market during the forecast period due to escalating pharmaceutical investments and research activities in gene and immunotherapy treatments. The Asia Pacific region shows promising growth with increased healthcare expenditure and the adoption of new technologies. Europe demonstrates substantial demand for RNAi drugs owing to intensive research activities in gene and immunotherapy treatments.
Segmentation Analysis:
The report covers sub-markets based on type (siRNA, miRNA), application (genetic disorders, oncology, neurodegenerative disorders, infectious diseases, renal diseases, and others), route of administration (intradermal, pulmonary, intravenous injections), and end users (diagnostic laboratories, research, and academic laboratories, hospitals).
Company Profiles:
Infinium Global Research profiles market leaders including Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., and others, providing insights into their market strategies and contributions.
Enquire Here Get Customization & Check the Discount for the Report @ https://www.infiniumglobalresearch.com/market-reports/customization/404
Table of Content
Chapter 1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
Chapter 2. Executive Summary
2.1. RNAi Therapeutics Market Highlights
2.2. RNAi Therapeutics Market Projection
2.3. RNAi Therapeutics Market Regional Highlights
Chapter 3. Global RNAi Therapeutics Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter`s Five Forces Analysis
3.4. IGR-Growth Matrix Analysis
3.4.1. IGR-Growth Matrix Analysis by Type
3.4.2. IGR-Growth Matrix Analysis by Application
3.4.3. IGR-Growth Matrix Analysis by Route of Administration
3.4.4. IGR-Growth Matrix Analysis by End User
3.4.5. IGR-Growth Matrix Analysis by Region
3.5. Value Chain Analysis of RNAi Therapeutics Market
Chapter 4. RNAi Therapeutics Market Macro Indicator Analysis
Chapter 5. Company Profiles and Competitive Landscape
5.1. Competitive Landscape in the Global RNAi Therapeutics Market
5.2. Companies Profiles
5.2.1. Alnylam Pharmaceuticals, Inc.
5.2.2. QIAGEN
5.2.3. Olix Pharmaceuticals, Inc.
5.2.4. Arbutus Biopharma
5.2.5. Silence Therapeutics
5.2.6. Dicerna Pharmaceuticals, Inc
5.2.7. Arrowhead Pharmaceuticals, Inc.
5.2.8. Quark Software Inc.
5.2.9. Phio Pharmaceuticals
5.2.10. Benitec Biopharma Ltd
Chapter 6. Global RNAi Therapeutics Market by Type
6.1. Small interfering RNA (siRNA)
6.2. MicroRNA (miRNA)
Chapter 7. Global RNAi Therapeutics Market by Application
7.1. Genetic Disorders
7.2. Oncology
7.3. Neurodegenerative Disorders
7.4. Infectious Diseases
7.5. Renal Diseases
7.6. Others
Chapter 8. Global RNAi Therapeutics Market by Route of Administration
8.1. Intradermal Injections
8.2. Pulmonary Delivery
8.3. Intravenous Injections
Chapter 9. Global RNAi Therapeutics Market by End User
9.1. Diagnostic Laboratories
9.2. Research and Academic Laboratories
9.3. Hospitals
Chapter 10. Global RNAi Therapeutics Market by Region 2023-2030
10.1. North America
10.1.1. North America RNAi Therapeutics Market by Type
10.1.2. North America RNAi Therapeutics Market by Application
10.1.3. North America RNAi Therapeutics Market by Route of Administration
10.1.4. North America RNAi Therapeutics Market by End User
10.1.5. North America RNAi Therapeutics Market by Country
10.1.5.1. The U.S. RNAi Therapeutics Market
10.1.5.1.1. The U.S. RNAi Therapeutics Market by Type
10.1.5.1.2. The U.S. RNAi Therapeutics Market by Application
10.1.5.1.3. The U.S. RNAi Therapeutics Market by Route of Administration
10.1.5.1.4. The U.S. RNAi Therapeutics Market by End User
10.1.5.2. Canada RNAi Therapeutics Market
10.1.5.2.1. Canada RNAi Therapeutics Market by Type
10.1.5.2.2. Canada RNAi Therapeutics Market by Application
10.1.5.2.3. Canada RNAi Therapeutics Market by Route of Administration
10.1.5.2.4. Canada RNAi Therapeutics Market by End User
10.1.5.3. Mexico RNAi Therapeutics Market
10.1.5.3.1. Mexico RNAi Therapeutics Market by Type
10.1.5.3.2. Mexico RNAi Therapeutics Market by Application
10.1.5.3.3. Mexico RNAi Therapeutics Market by Route of Administration
10.1.5.3.4. Mexico RNAi Therapeutics Market by End User
10.2. Europe
10.2.1. Europe RNAi Therapeutics Market by Type
10.2.2. Europe RNAi Therapeutics Market by Application
10.2.3. Europe RNAi Therapeutics Market by Route of Administration
10.2.4. Europe RNAi Therapeutics Market by End User
10.2.5. Europe RNAi Therapeutics Market by Country
10.2.5.1. Germany RNAi Therapeutics Market
10.2.5.1.1. Germany RNAi Therapeutics Market by Type
10.2.5.1.2. Germany RNAi Therapeutics Market by Application
10.2.5.1.3. Germany RNAi Therapeutics Market by Route of Administration
10.2.5.1.4. Germany RNAi Therapeutics Market by End User
10.2.5.2. United Kingdom RNAi Therapeutics Market
10.2.5.2.1. United Kingdom RNAi Therapeutics Market by Type
10.2.5.2.2. United Kingdom RNAi Therapeutics Market by Application
10.2.5.2.3. United Kingdom RNAi Therapeutics Market by Route of Administration
10.2.5.2.4. United Kingdom RNAi Therapeutics Market by End User
10.2.5.3. France RNAi Therapeutics Market
10.2.5.3.1. France RNAi Therapeutics Market by Type
10.2.5.3.2. France RNAi Therapeutics Market by Application
10.2.5.3.3. France RNAi Therapeutics Market by Route of Administration
10.2.5.3.4. France RNAi Therapeutics Market by End User
10.2.5.4. Italy RNAi Therapeutics Market
10.2.5.4.1. Italy RNAi Therapeutics Market by Type
10.2.5.4.2. Italy RNAi Therapeutics Market by Application
10.2.5.4.3. Italy RNAi Therapeutics Market by Route of Administration
10.2.5.4.4. Italy RNAi Therapeutics Market by End User
10.2.5.5. Rest of Europe RNAi Therapeutics Market
10.2.5.5.1. Rest of Europe RNAi Therapeutics Market by Type
10.2.5.5.2. Rest of Europe RNAi Therapeutics Market by Application
10.2.5.5.3. Rest of Europe RNAi Therapeutics Market by Route of Administration
10.2.5.5.4. Rest of Europe RNAi Therapeutics Market by End User
10.3. Asia Pacific
10.3.1. Asia Pacific RNAi Therapeutics Market by Type
10.3.2. Asia Pacific RNAi Therapeutics Market by Application
10.3.3. Asia Pacific RNAi Therapeutics Market by Route of Administration
10.3.4. Asia Pacific RNAi Therapeutics Market by End User
10.3.5. Asia Pacific RNAi Therapeutics Market by Country
10.3.5.1. China RNAi Therapeutics Market
10.3.5.1.1. China RNAi Therapeutics Market by Type
10.3.5.1.2. China RNAi Therapeutics Market by Application
10.3.5.1.3. China RNAi Therapeutics Market by Route of Administration
10.3.5.1.4. China RNAi Therapeutics Market by End User
10.3.5.2. Japan RNAi Therapeutics Market
10.3.5.2.1. Japan RNAi Therapeutics Market by Type
10.3.5.2.2. Japan RNAi Therapeutics Market by Application
10.3.5.2.3. Japan RNAi Therapeutics Market by Route of Administration
10.3.5.2.4. Japan RNAi Therapeutics Market by End User
10.3.5.3. India RNAi Therapeutics Market
10.3.5.3.1. India RNAi Therapeutics Market by Type
10.3.5.3.2. India RNAi Therapeutics Market by Application
10.3.5.3.3. India RNAi Therapeutics Market by Route of Administration
10.3.5.3.4. India RNAi Therapeutics Market by End User
10.3.5.4. South Korea RNAi Therapeutics Market
10.3.5.4.1. South Korea RNAi Therapeutics Market by Type
10.3.5.4.2. South Korea RNAi Therapeutics Market by Application
10.3.5.4.3. South Korea RNAi Therapeutics Market by Route of Administration
10.3.5.4.4. South Korea RNAi Therapeutics Market by End User
10.3.5.5. Australia RNAi Therapeutics Market
10.3.5.5.1. Australia RNAi Therapeutics Market by Type
10.3.5.5.2. Australia RNAi Therapeutics Market by Application
10.3.5.5.3. Australia RNAi Therapeutics Market by Route of Administration
10.3.5.5.4. Australia RNAi Therapeutics Market by End User
10.3.5.6. Rest of Asia-Pacific RNAi Therapeutics Market
10.3.5.6.1. Rest of Asia-Pacific RNAi Therapeutics Market by Type
10.3.5.6.2. Rest of Asia-Pacific RNAi Therapeutics Market by Application
10.3.5.6.3. Rest of Asia-Pacific RNAi Therapeutics Market by Route of Administration
10.3.5.6.4. Rest of Asia-Pacific RNAi Therapeutics Market by End User
10.4. RoW
10.4.1. RoW RNAi Therapeutics Market by Type
10.4.2. RoW RNAi Therapeutics Market by Application
10.4.3. RoW RNAi Therapeutics Market by Route of Administration
10.4.4. RoW RNAi Therapeutics Market by End User
10.4.5. RoW RNAi Therapeutics Market by Sub-region
10.4.5.1. Latin America RNAi Therapeutics Market
10.4.5.1.1. Latin America RNAi Therapeutics Market by Type
10.4.5.1.2. Latin America RNAi Therapeutics Market by Application
10.4.5.1.3. Latin America RNAi Therapeutics Market by Route of Administration
10.4.5.1.4. Latin America RNAi Therapeutics Market by End User
10.4.5.2. Middle East RNAi Therapeutics Market
10.4.5.2.1. Middle East RNAi Therapeutics Market by Type
10.4.5.2.2. Middle East RNAi Therapeutics Market by Application
10.4.5.2.3. Middle East RNAi Therapeutics Market by Route of Administration
10.4.5.2.4. Middle East RNAi Therapeutics Market by End User
10.4.5.3. Africa RNAi Therapeutics Market
10.4.5.3.1. Africa RNAi Therapeutics Market by Type
10.4.5.3.2. Africa RNAi Therapeutics Market by Application
10.4.5.3.3. Africa RNAi Therapeutics Market by Route of Administration
10.4.5.3.4. Africa RNAi Therapeutics Market by End User
More Insights on this report, Speak to Our Analyst: https://www.infiniumglobalresearch.com/market-reports/enquiry/404
Reasons to Buy this Report:
=> Comprehensive analysis of global as well as regional markets of RNAi therapeutics.
=> Complete coverage of all the product types and application segments to analyze the trends, developments, and forecast of market size up to 2030.
=> Comprehensive analysis of the companies operating in this market. The company profile includes an analysis of the product portfolio, revenue, SWOT analysis, and the latest developments of the company.
=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus on to invest, consolidate, expand, and/or diversify.
2nd Floor, Ganadish Empire, Rahatani Chowk, Pimple Saudagar, Pimpri-Chinchwad, Maharashtra 411027
About Infinium Global Research:
Infinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes, and non-profit/non-government organizations to meet their knowledge and information needs.
Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations, and the environment, Infinium often conducts regular meets with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global RNAi Therapeutics Market is Forecast to Reach a Value of USD 20.23 Billion By 2030 with a Growing CAGR of 7.69% | Infinium Global Research here
News-ID: 3317949 • Views: …
More Releases from Infinium Global Research LLP
Global Sterilization Services Market Size Worth USD 12.55 Billion By 2030 | CAGR …
Infinium Global Research, a leading provider of market intelligence, has recently launched an in-depth report on the Global Sterilization Services Market, offering comprehensive analysis and detailed insights into its segments and market trends.
The comprehensive study explores the impact of various factors such as drivers, restraints, and macro indicators on both the global and regional sterilization services market, providing crucial forecasts and dollar value projections.
To Know More Request a Sample of…
Global Proprotein Convertase Subtilisin/Kexin Type 9 Market is Projected to Surp …
Infinium Global Research introduces a detailed analysis of the global and regional Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) market, providing an extensive study of its segments, trends, forecasts, and dollar values in their latest report. This comprehensive study empowers stakeholders in the pharmaceutical and healthcare sectors with invaluable insights into this burgeoning market.
To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/market-reports/sample-request/420
Market Insight:
The global Proprotein Convertase Subtilisin/Kexin Type 9 market,…
Global Neuromodulation Market is Anticipated to Reach USD 7.27 Billion and Growi …
Infinium Global Research, a pioneering market intelligence firm, introduces a comprehensive report delving into the Global Neuromodulation Market, providing extensive analysis and in-depth exploration of its segments, market trends, and projections.
To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/market-reports/sample-request/93
Market Insight:
The global neuromodulation market, valued at USD 3.51 Billion in 2022, is poised to ascend to USD 7.27 Billion by 2030, exhibiting a noteworthy CAGR of 9.59% during the forecast…
Global Botulinum Toxin Market Growing at a CAGR of 9.12% to Reach USD 20.09 Bill …
Infinium Global Research, a leading market intelligence firm, has released an extensive report delving into the dynamics and trends shaping the Global Botulinum Toxin Market. This comprehensive analysis spans both the global landscape and regional perspectives, providing invaluable insights into the market's trajectory, influencing factors, and growth projections.
To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/market-reports/sample-request/89
Market Insight:
The global botulinum toxin market, valued at USD 10.02 billion in 2022, is…
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…
